Symbols / OCEA $0.00 +0.00% Ocean Biomedical, Inc.

Healthcare • Biotechnology • United States • PNK
OCEA Chart
About

Ocean Biomedical, Inc., a biopharmaceutical company, focuses on discovering and developing therapeutic products in oncology, fibrosis, and infectious diseases in the United States. The company's oncology product candidates include OCX-253 anti-Chi3l1 Single-target mAb and OCX-410 anti-Chi3l1/PD-1 Bi-specific antibody for the treatment of non-small cell lung cancer; and OCX-909 anti-Chi3l1/CTLA-4 Bi-specific antibody to treat glioblastoma multiforme. Its fibrosis product candidates consist of OCF-203 anti-Chit1 small molecule for the treatment of idiopathic pulmonary fibrosis (IPF) and hermansky-pudlak syndrome (HPS). The company's infectious diseases product candidates for malaria include the ODA-570 vaccine for the prevention of P. falciparum infection; ODA-611 anti-PfGARP mAb for the treatment of Symptomatic P. falciparum infection; and ODA-579 anti-PfGARP small molecule for the treatment of Symptomatic P. falciparum infection. It has license agreement with Elkurt, Inc. for FRG Antibody, bi-specific antibody anti-CTLA4, bispecific (FRG)x anti-PD-1 (FRGxPD-1), chit1 small molecule antifibrotic, and malaria small molecules and antibodies. The company was founded in 2019 and is based in Providence, Rhode Island. Ocean Biomedical, Inc. is a subsidiary of Poseidon Bio, LLC.

Fundamentals
Scroll to Statements
Sector Healthcare Industry Biotechnology Market Cap 69.71K
Enterprise Value — Income -30.72M Sales —
Book/sh -0.56 Cash/sh — Dividend Yield —
Payout 0.00% Employees 7 IPO —
P/E — Forward P/E -0.00 PEG —
P/S — P/B -0.00 P/C —
EV/EBITDA — EV/Sales — Quick Ratio —
Current Ratio 0.06 Debt/Eq — LT Debt/Eq —
EPS (ttm) -0.91 EPS next Y -0.89 EPS Growth —
Revenue Growth — Earnings 2024-04-15 17:00 ROA -114.87%
ROE — ROIC — Gross Margin 0.00%
Oper. Margin 0.00% Profit Margin 0.00% Shs Outstand 232.37M
Shs Float 208.41M Short Float 2.05% Short Ratio 0.05
Short Interest — 52W High 0.05 52W Low 0.00
Beta 0.41 Avg Volume 68.77K Volume 7.78K
Target Price — Recom None Prev Close $0.00
Price $0.00 Change 0.00%
Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
—
Mean price target
2. Current target
$0.00
Latest analyst target
3. DCF / Fair value
$-0.41
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$0.00
Low
—
High
—
Mean
—

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2023-05-31 init Taglich Brothers — → Speculative Buy $20
2023-04-27 main EF Hutton — → Buy $17
2023-04-13 reit EF Hutton — → Buy $10
2023-03-16 init Fundamental Research Corp. — → Buy $16
2023-03-13 init EF Hutton — → Buy $10
News
RSS: Latest OCEA news
Insider Transactions

No recent insider transactions.

Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total Revenue
0.00
0.00
0.00
0.00
Operating Revenue
0.00
0.00
0.00
0.00
Operating Expense
3.80
-62.82%
10.21
-36.64%
16.12
-74.14%
62.34
Research And Development
0.03
-96.33%
0.71
-91.57%
8.41
-75.22%
33.93
Selling General And Administration
3.77
-60.32%
9.51
+23.25%
7.71
-72.86%
28.41
General And Administrative Expense
3.77
-60.32%
9.51
+23.25%
7.71
-72.86%
28.41
Other Gand A
3.77
-60.32%
9.51
+23.25%
7.71
-72.86%
28.41
Other Operating Expenses
—
—
2.48
—
Total Expenses
3.80
-62.82%
10.21
-36.64%
16.12
-74.14%
62.34
Operating Income
-3.80
+62.82%
-10.21
+36.64%
-16.12
+74.14%
-62.34
Total Operating Income As Reported
-3.80
+62.82%
-10.21
+36.64%
-16.12
+74.14%
-62.34
EBITDA
-7.43
+93.40%
-112.70
-599.33%
-16.12
+74.15%
-62.34
Normalized EBITDA
-3.54
+71.54%
-12.44
+22.81%
-16.12
+74.15%
-62.34
EBIT
-7.43
+93.40%
-112.70
-599.33%
-16.12
+74.15%
-62.34
Total Unusual Items
-3.89
+96.12%
-100.26
0.00
—
Total Unusual Items Excluding Goodwill
-3.89
+96.12%
-100.26
0.00
—
Special Income Charges
-0.36
+99.02%
-36.49
0.00
—
Other Special Charges
—
15.08
—
—
Restructuring And Mergern Acquisition
0.36
-98.34%
21.41
0.00
—
Net Income
-9.48
+91.72%
-114.47
-559.40%
-17.36
+72.16%
-62.34
Pretax Income
-9.48
+91.72%
-114.47
-559.40%
-17.36
+72.16%
-62.34
Net Non Operating Interest Income Expense
-2.05
-16.12%
-1.76
-41.75%
-1.24
—
Interest Expense Non Operating
2.05
+16.12%
1.76
+41.75%
1.24
—
Net Interest Income
-2.05
-16.12%
-1.76
-41.75%
-1.24
—
Interest Expense
2.05
+16.12%
1.76
+41.75%
1.24
—
Interest Income Non Operating
—
—
1.52
—
Interest Income
—
—
1.52
—
Other Income Expense
-3.64
+96.45%
-102.49
-2049900.00%
0.01
+400.00%
0.00
Other Non Operating Income Expenses
3.56
+334.39%
-1.52
-30460.00%
0.01
+400.00%
0.00
Gain On Sale Of Security
-3.54
+94.45%
-63.78
—
—
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-9.48
+91.72%
-114.47
-559.40%
-17.36
+72.16%
-62.34
Net Income From Continuing Operation Net Minority Interest
-9.48
+91.72%
-114.47
-559.40%
-17.36
+72.16%
-62.34
Net Income From Continuing And Discontinued Operation
-9.48
+91.72%
-114.47
-559.40%
-17.36
+72.16%
-62.34
Net Income Continuous Operations
-9.48
+91.72%
-114.47
-559.40%
-17.36
+72.16%
-62.34
Normalized Income
-5.59
+60.66%
-14.20
+18.19%
-17.36
+72.16%
-62.34
Net Income Common Stockholders
-9.48
+91.72%
-114.47
-559.40%
-17.36
+72.16%
-62.34
Diluted EPS
-0.34
+92.18%
-4.35
-406.28%
-0.86
+72.16%
-3.09
Basic EPS
-0.34
+92.18%
-4.35
-406.28%
-0.86
+72.16%
-3.09
Basic Average Shares
27.50
+4.60%
26.29
-27.96%
36.50
+80.64%
20.20
Diluted Average Shares
27.50
+4.60%
26.29
-27.96%
36.50
+80.64%
20.20
Diluted NI Availto Com Stockholders
-9.48
+91.72%
-114.47
-559.40%
-17.36
+72.16%
-62.34
Earnings From Equity Interest
-3.30
-366.24%
-0.71
—
—
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Total Assets
0.90
-83.60%
5.50
+198.64%
1.84
-98.30%
108.65
Current Assets
0.81
-61.50%
2.11
+14.50%
1.84
+18.85%
1.55
Cash Cash Equivalents And Short Term Investments
0.00
-100.00%
0.00
-88.24%
0.03
-96.84%
1.08
Cash And Cash Equivalents
0.00
-100.00%
0.00
-88.24%
0.03
-96.84%
1.08
Cash Financial
0.00
-100.00%
0.00
-88.24%
0.03
-96.84%
1.08
Receivables
—
—
0.05
0.00
Prepaid Assets
0.59
-46.79%
1.10
0.00
-100.00%
0.47
Current Deferred Assets
—
0.00
-100.00%
1.81
+9415.79%
0.02
Restricted Cash
0.22
-77.60%
1.00
0.00
—
Total Non Current Assets
0.09
-97.35%
3.39
0.00
-100.00%
107.10
Investments And Advances
0.09
-97.35%
3.39
0.00
—
Other Non Current Assets
—
—
110.44
+3.12%
107.10
Total Liabilities Net Minority Interest
98.52
+2.34%
96.26
+660.32%
12.66
+272.77%
3.40
Current Liabilities
33.89
+12.92%
30.01
+137.04%
12.66
+5037.48%
0.25
Payables And Accrued Expenses
16.50
-3.68%
17.13
+44.14%
11.88
+4722.60%
0.25
Payables
0.80
-14.36%
0.93
+187.23%
0.32
+843.06%
0.03
Accounts Payable
0.80
-14.36%
0.93
0.00
-100.00%
0.03
Current Accrued Expenses
15.70
-3.07%
16.20
+36.29%
11.88
+5506.13%
0.21
Current Debt And Capital Lease Obligation
16.30
+34.51%
12.12
+1461.60%
0.78
—
Current Debt
16.30
+34.51%
12.12
+1461.60%
0.78
—
Other Current Borrowings
14.07
+69.21%
8.32
+971.91%
0.78
—
Other Current Liabilities
1.09
+42.73%
0.76
—
—
Total Non Current Liabilities Net Minority Interest
64.63
-2.45%
66.25
0.00
-100.00%
3.15
Non Current Deferred Liabilities
—
—
3.15
+0.00%
3.15
Other Non Current Liabilities
5.57
-27.89%
7.73
—
—
Stockholders Equity
-97.62
-7.55%
-90.76
-738.92%
-10.82
-110.28%
105.26
Common Stock Equity
-97.62
-7.55%
-90.76
-738.92%
-10.82
-110.28%
105.26
Capital Stock
0.00
0.00
0.00
-100.00%
107.10
Common Stock
0.00
0.00
0.00
-100.00%
107.10
Preferred Stock
—
—
0.00
0.00
Share Issued
34.87
+0.63%
34.65
+2.59%
33.77
+67.17%
20.20
Ordinary Shares Number
34.87
+0.63%
34.65
+2.59%
33.77
+67.17%
20.20
Additional Paid In Capital
107.92
+2.49%
105.29
+48.78%
70.77
+5627.76%
-1.28
Retained Earnings
-205.53
-4.84%
-196.06
-140.30%
-81.59
-14363.31%
-0.56
Total Equity Gross Minority Interest
-97.62
-7.55%
-90.76
-738.92%
-10.82
-110.28%
105.26
Total Capitalization
-97.62
-7.55%
-90.76
-738.92%
-10.82
-110.28%
105.26
Working Capital
-33.08
-18.54%
-27.90
-157.91%
-10.82
-930.03%
1.30
Invested Capital
-81.32
-3.40%
-78.64
-683.08%
-10.04
-109.54%
105.26
Total Debt
16.30
+34.51%
12.12
+1461.60%
0.78
—
Net Debt
16.30
+34.56%
12.11
+1532.61%
0.74
—
Net Tangible Assets
-97.62
-7.55%
-90.76
-738.92%
-10.82
-110.28%
105.26
Tangible Book Value
-97.62
-7.55%
-90.76
-738.92%
-10.82
-110.28%
105.26
Current Notes Payable
2.23
-41.45%
3.80
—
—
Derivative Product Liabilities
59.06
+0.91%
58.52
0.00
—
Duefrom Related Parties Current
—
—
0.05
0.00
Line Item Trend 2024-12-31 2023-12-31 2022-12-31 2021-12-31
Operating Cash Flow
-4.18
+55.67%
-9.43
-849.55%
-0.99
+5.70%
-1.05
Cash Flow From Continuing Operating Activities
-4.18
+55.67%
-9.43
-849.55%
-0.99
+5.70%
-1.05
Net Income From Continuing Operations
-9.48
+91.72%
-114.47
-559.40%
-17.36
+72.16%
-62.34
Other Non Cash Items
-3.33
-121.45%
15.51
+1569.43%
0.93
—
Stock Based Compensation
0.74
-38.17%
1.21
-90.26%
12.38
-78.11%
56.55
Operating Gains Losses
5.37
-93.92%
88.31
+35225.20%
0.25
—
Gain Loss On Investment Securities
1.98
-96.95%
64.95
+25878.80%
0.25
—
Unrealized Gain Loss On Investment Securities
1.47
+225.45%
-1.17
0.00
—
Net Foreign Currency Exchange Gain Loss
0.09
0.00
—
—
Change In Working Capital
1.04
-11.69%
1.18
-57.96%
2.81
-40.75%
4.74
Change In Prepaid Assets
0.52
+199.61%
-0.52
-234.94%
0.38
—
Change In Payables And Accrued Expense
0.53
-69.06%
1.70
-39.48%
2.81
—
Change In Accrued Expense
-0.34
-173.45%
0.47
0.00
—
Change In Payable
0.87
-29.52%
1.23
-56.11%
2.81
—
Change In Account Payable
0.87
-29.52%
1.23
-56.11%
2.81
—
Investing Cash Flow
—
—
-2.10
0.00
Cash Flow From Continuing Investing Activities
—
—
-2.10
—
Gain Loss On Sale Of Business
0.00
-100.00%
7.58
0.00
—
Net Other Investing Changes
—
—
-2.10
—
Financing Cash Flow
3.40
-67.30%
10.40
+975.39%
0.97
-13.12%
1.11
Cash Flow From Continuing Financing Activities
3.40
-67.30%
10.40
+975.39%
0.97
-13.12%
1.11
Net Issuance Payments Of Debt
3.40
-50.06%
6.81
+826.26%
0.73
—
Issuance Of Debt
3.40
-61.83%
8.91
+1111.97%
0.73
—
Repayment Of Debt
0.00
+100.00%
-2.10
0.00
—
Long Term Debt Issuance
3.40
+423.08%
0.65
0.00
—
Long Term Debt Payments
—
—
0.00
—
Net Long Term Debt Issuance
3.40
+423.08%
0.65
0.00
—
Short Term Debt Issuance
0.00
-100.00%
8.26
+1023.54%
0.73
—
Short Term Debt Payments
0.00
+100.00%
-2.10
0.00
—
Net Short Term Debt Issuance
0.00
-100.00%
6.16
+737.82%
0.73
—
Net Common Stock Issuance
0.00
+100.00%
-48.51
0.00
-100.00%
1.02
Common Stock Payments
0.00
+100.00%
-64.28
0.00
—
Repurchase Of Capital Stock
0.00
+100.00%
-64.28
0.00
—
Proceeds From Stock Option Exercised
—
—
0.00
—
Net Other Financing Charges
—
52.10
+22359.05%
0.23
+141.67%
0.10
Changes In Cash
-0.78
-180.41%
0.97
+3830.77%
-0.03
-143.33%
0.06
Beginning Cash Position
1.00
+2852.94%
0.03
-43.33%
0.06
0.00
End Cash Position
0.22
-77.69%
1.00
+2852.94%
0.03
-43.33%
0.06
Free Cash Flow
-4.18
+55.67%
-9.43
-849.55%
-0.99
+5.70%
-1.05
Common Stock Issuance
0.00
-100.00%
15.77
0.00
-100.00%
1.02
Earnings Losses From Equity Investments
3.30
+366.24%
0.71
0.00
—
Issuance Of Capital Stock
0.00
-100.00%
15.77
0.00
-100.00%
1.02
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category